Free Trial

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

-0.14 (-2.42%)
(As of 02:51 PM ET)
Today's Range
50-Day Range
52-Week Range
756,499 shs
Average Volume
2.04 million shs
Market Capitalization
$804.60 million
P/E Ratio
Dividend Yield
Price Target

Aurinia Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
75.4% Upside
$10.00 Price Target
Short Interest
8.11% of Float Sold Short
Dividend Strength
News Sentiment
0.87mentions of Aurinia Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.15 to $0.53 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.83 out of 5 stars

Medical Sector

403rd out of 921 stocks

Pharmaceutical Preparations Industry

173rd out of 419 stocks

AUPH stock logo

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

AUPH Stock Price History

AUPH Stock News Headlines

Top 4 Pharma Stocks to Consider This Month
11 Oversold Biotech Stocks To Buy Right Now
AUPH Mar 2024 3.000 call
See More Headlines
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$175.51 million
Book Value
$2.63 per share


Free Float
Market Cap
$824.57 million
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

AUPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Aurinia Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings
or view top-rated stocks.

What is Aurinia Pharmaceuticals' stock price target for 2024?

4 equities research analysts have issued 12-month price targets for Aurinia Pharmaceuticals' shares. Their AUPH share price targets range from $8.00 to $13.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price.
View analysts price targets for AUPH
or view top-rated stocks among Wall Street analysts.

How have AUPH shares performed in 2024?

Aurinia Pharmaceuticals' stock was trading at $8.99 at the start of the year. Since then, AUPH stock has decreased by 36.6% and is now trading at $5.70.
View the best growth stocks for 2024 here

When is Aurinia Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our AUPH earnings forecast

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its quarterly earnings data on Thursday, February, 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. The biotechnology company earned $45.10 million during the quarter, compared to analysts' expectations of $45 million. Aurinia Pharmaceuticals had a negative net margin of 32.69% and a negative trailing twelve-month return on equity of 15.06%. The firm's quarterly revenue was up 58.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.18) earnings per share.

What ETF holds Aurinia Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 42,195 shares of AUPH stock, representing 1.15% of its portfolio.

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Who are Aurinia Pharmaceuticals' major shareholders?

Aurinia Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.07%), GSA Capital Partners LLP (0.24%), Nordea Investment Management AB (0.22%), Jupiter Asset Management Ltd. (0.17%), Simplex Trading LLC (0.00%) and Sunbelt Securities Inc. (0.13%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AUPH) was last updated on 5/21/2024 by Staff

From Our Partners